Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Jinsai Pharmaceutical received marketing authorization from China's National Medical Products Administration for its Jintuximab Injection, according to a Wednesday filing with the Shanghai bourse.
The drug is indicated in combination with paclitaxel for patients with advanced gastric or gastroesophageal junction adenocarcinoma.